News
KTRA
--
0.00%
--
Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference
SAN DIEGO, May 5, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, May 5, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical...
PR Newswire - PRF · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 3d ago
Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
, /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of to the Company's Board of Directors r...
PR Newswire - PRF · 3d ago
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 3d ago
Kintara glioblastoma candidate VAL-083 benefits progression-free survival
Interim data from two phase 2 trials of Kintara Therapeutics' (KTRA) glioblastoma multiforme (GBM) candidate VAL-083 showed that the drug extends progression-free survival ("PFS") compared to a standard of care.In the
Seekingalpha · 04/12 13:29
Kintara Highlights Updates On Two Phase 2 Clinical Trials Of VAL-083 At 2021 American Association For Cancer Research Annual Meeting
 Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current
Benzinga · 04/12 12:03
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting
SAN DIEGO, April 12, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the...
PR Newswire - PRF · 04/12 12:00
Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies
Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021. 
Benzinga · 04/05 14:51
Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference
Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday.
Benzinga · 03/25 18:45
BRIEF-Kintara Therapeutics Inc Files For Mixed Shelf Of Upto $100 Million - SEC Filing
reuters.com · 03/24 22:17
Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021
9:25 a.m. EDT - Lantern Pharma (LTRN) CEO, Panna Sharma 9:25 a.m. - AcelRx Pharma (ACRX) CEO, Vincent Angotti 9:45 a.m. - Kintara Therapeutics (KTRA) CEO, Saiid Zarrabian 9:45 a.m. - Lexaria Bioscience (LEXX) Chair,
Benzinga · 03/23 23:12
Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that its Chief Executive Officer Saiid Zarrabian will participate in the Ben...
PR Newswire · 03/17 13:00
Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer
SAN DIEGO, March 3, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the...
PR Newswire - PRF · 03/03 13:01
Kintara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces that its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Glo...
PR Newswire · 03/02 13:00
KTRA: 2Q:21 Update & Target Price Increase
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Second Quarter Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced second quarter financial and operational results in a February 12t...
Zacks Small Cap Research · 03/01 10:36
Kintara Therapeutics (KTRA) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Kintara Therapeutics (KTRA), with a price target of $6.00. The
SmarterAnalyst · 02/18 19:05
Kintara Therapeutics Concludes Enrollment In Recurrent Arm Of VAL-083 Mid-Stage Brain Cancer Study
Benzinga · 02/17 17:56
Thinking about buying stock in PAVmed, Kintara Therapeutics, Seelos Therapeutics, Novan, or Verastem?
NEW YORK, Feb. 17, 2021 /PRNewswire via COMTEX/ -- NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PAVM,...
PR Newswire - PRF · 02/17 14:31
BRIEF-Kintara Therapeutics Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For Recurrent Gbm
reuters.com · 02/17 13:19
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the recurrent arm of its ongoing Phase ...
PR Newswire · 02/17 13:00
Webull provides a variety of real-time KTRA stock news. You can receive the latest news about Kintara Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).